Literature DB >> 3001337

Modification of Epstein-Barr virus replication by tunicamycin.

L M Hutt-Fletcher, N Balachandran, P A LeBlanc.   

Abstract

The effect of tunicamycin, which inhibits N-linked glycosylation, on the replication of Epstein-Barr virus was examined. Tunicamycin markedly reduced the yield of virus from producing cells. At concentrations of 1 to 2 micrograms of tunicamycin per ml, there was a buildup of intracellular virus in P3HR1-Cl13 cells but not in MCUV5 cells; at a concentration of 5 micrograms of tunicamycin per ml in P3HR1-Cl13 cells, viral DNA synthesis was inhibited as well. Viral glycoproteins lacking N-linked sugars were apparently inserted into the cell membrane, and the small amount of virus made in the presence of drug was able to bind specifically to its receptor on B cells. However, the ability of the virus to induce immunoglobulin secretion by fresh human lymphocytes was impaired. This implies a role for viral glycoproteins in the penetration as well as the attachment of virus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3001337      PMCID: PMC252705     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity.

Authors:  M Sarmiento; M Haffey; P G Spear
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

Review 2.  A new approach to the study of human B lymphocyte function using an indirect plaque assay and a direct B cell activator.

Authors:  A G Bird; S Britton
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  Effect of tunicamycin on herpes simplex virus glycoproteins and infectious virus production.

Authors:  L I Pizer; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

4.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

5.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

6.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

7.  The specific site of tunicamycin inhibition in the formation of dolichol-bound N-acetylglucosamine derivatives.

Authors:  L Lehle; W Tanner
Journal:  FEBS Lett       Date:  1976-11-15       Impact factor: 4.124

8.  Adsorption and penetration of enveloped herpes simplex virus particles modified by tunicamycin or 2-deoxy-D-glucose.

Authors:  B Svennerholm; S Olofsson; R Lundén; A Vahlne; E Lycke
Journal:  J Gen Virol       Date:  1982-12       Impact factor: 3.891

9.  Determination of nucleic acid sequence homologies and relative concentrations by a dot hybridization procedure.

Authors:  F C Kafatos; C W Jones; A Efstratiadis
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  10 in total

1.  Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect.

Authors:  X Wang; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

2.  Localization of Epstein-Barr virus envelope glycoproteins on the inner nuclear membrane of virus-producing cells.

Authors:  M R Torrisi; M Cirone; A Pavan; C Zompetta; G Barile; L Frati; A Faggioni
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

4.  Synergistic activation of cells by Epstein-Barr virus and B-cell growth factor.

Authors:  L M Hutt-Fletcher
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

5.  Detection by monoclonal antibodies of an early membrane protein induced by Epstein-Barr virus.

Authors:  N Balachandran; J Pittari; L M Hutt-Fletcher
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

6.  Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate.

Authors:  F Z Wang; S M Akula; N P Pramod; L Zeng; B Chandran
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus.

Authors:  N Balachandran; D E Oba; L M Hutt-Fletcher
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

8.  Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells.

Authors:  X Wang; W J Kenyon; Q Li; J Müllberg; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 9.  Inhibitors of protein glycosylation and glycoprotein processing in viral systems.

Authors:  R Datema; S Olofsson; P A Romero
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

10.  A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.

Authors:  Fernando Santos-Beneit; Vytautas Raškevičius; Vytenis A Skeberdis; Sergio Bordel
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.